Hernandez-Pastor, Luis
Geurtsen, Jeroen
Baugh, Bryan
El Khoury, Antoine C.
Kalu, Nnanya
Gauthier-Loiselle, Marjolaine
Bungay, Rebecca
Cloutier, Martin
Sarnecki, Michal
Saade, Elie
Funding for this research was provided by:
Janssen Global Services, LLC (Not Applicable, Not Applicable, Not Applicable, Not Applicable, Not Applicable, Not Applicable, Not Applicable, Not Applicable, Not Applicable)
Article History
Received: 9 February 2023
Accepted: 22 July 2023
First Online: 22 August 2023
Declarations
:
: The study was conducted using de-identified, commercially available secondary healthcare database that complies with the requirements of the Health Insurance Portability and Accountability Act of 1996. Therefore, ethics approval and consent to participate are not applicable for the current study per Title 45 of Code of Federal Regulation, Part 46.101(b) [CitationRef removed] (ExternalRef removed). All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable since this manuscript did not involve any experiments on humans nor does it contain any identifiable data from individual patients.
: Luis Hernandez-Pastor is an employee of Janssen Pharmaceutica NV. Jeroen Geurtsen is an employee of Janssen Vaccines & Prevention BV. Bryan Baugh is an employee of Janssen Research & Development, LLC. Antoine C. El Khoury is an employee of Janssen Global Services, LLC. Nnanya Kalu is an employee of Janssen Scientific Affairs, LLC. Marjolaine Gauthier-Loiselle, Rebecca Bungay, and Martin Cloutier are employees of Analysis Group, Inc. a consulting company that has provided paid consulting services to Janssen Global Services, LLC., which funded the development and conduct of this study and manuscript. Michal Sarnecki is an employee of Janssen Vaccines, Branch of Cilag GmbH International. Elie Saade received consultation and speaker fees from Janssen.
: A portion of these results were presented at the IDWeek conference held in Washington, DC, USA, October 19–23, 2022.